Intra-Cellular Therapies, Inc.
ITCIDelisted Apr 2, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001567514
Intra-Cellular Therapies, Inc. was delisted on Apr 2, 2025; its insiders filed their last Form 4 on Apr 2, 2025; 395 institutions reported holding it in 13F filings for Q1 2025, worth $13.6B in total; Soros Fund Management was the only superinvestor holding it.
Q1 2022 vs. Q4 2021
How the institutions holding Intra-Cellular Therapies, Inc. changed between Q4 2021 and Q1 2022.
All holders in Q1 2022All holders in Q4 2021
| Measure | Q4 2021 | Of which not filed for Q1 2022 | Q1 2022 | Change |
|---|---|---|---|---|
| Holders | 208 | 2 | 241 | +35 |
| Shares | 69.0M | 76.3K | 80.8M | +11.9M (+17.2%) |
| Value | $3.60B | $3.99M | $4.94B | +$1.34B (+37.3%) |
2 institutions that held it in Q4 2021 haven't filed for Q1 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (66)
Institutions that held Intra-Cellular Therapies, Inc. at the end of Q1 2022 but not at the end of Q4 2021.
Sold out (31)
Institutions that held Intra-Cellular Therapies, Inc. at the end of Q4 2021 and filed for Q1 2022 without it.
Not filed for Q1 2022 yet (2)
Institutions that held Intra-Cellular Therapies, Inc. at the end of Q4 2021 and haven't filed a 13F for Q1 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2021 | Value, Q4 2021 |
|---|---|---|
| First Midwest Bank Trust Division | 76,281 | $3.99M |
| Bell Investment Advisors, Inc | 15 | $1.00K |